Freedom to Operate (FTO) Search: Everything You Should Know

A pharmaceutical company spends three years and several resources developing a new drug formulation. Clinical trials are complete, regulatory approval is in sight, and the product is ready for launch. Two weeks before the commercial rollout, the legal team identifies a granted Indian patent whose claims directly cover the formulation's key process step. The patent holder is a competitor.

Launching now means infringement. Pulling back means three years of investment sitting idle while the team figures out whether to redesign, negotiate a licence, or challenge the patent's validity. None of those options are fast, and none of them are cheap.

An FTO search conducted before the clinical trials began would have surfaced that patent years earlier, when the formulation could still have been designed around it at a fraction of the cost.

This is what Freedom to Operate analysis actually does in practice, and why the timing of when it is commissioned matters as much as whether it is done at all.

What a Freedom to Operate Search Actually Is

A Freedom to Operate search, also called a clearance search or infringement analysis, is a legal and technical review that answers one specific question: can a product or process be manufactured, offered for sale, sold, used in a specific market or imported in a particular jurisdiction without infringing patents held by third parties?

It is not a patentability search. A patentability search asks whether an invention is novel and eligible for patent protection. An FTO search asks something entirely different: whether an existing or planned commercial activity runs the risk of stepping on someone else's patent.

The distinction matters because the two searches look at different things. A patentability search reviews prior art broadly to assess novelty. An FTO search focuses specifically on the claims of active, in-force patents in the relevant jurisdiction and asks whether those claims, read carefully and technically, cover what the business is planning to do commercially.

A business can have a granted patent on its own invention and still infringe someone else's patent when it manufactures the product. This is one of the most commonly misunderstood aspects of patent law. A granted patent gives the holder the right to exclude others from using the invention. It does not automatically give the holder the right to commercialise it if doing so requires using a feature that falls within someone else's patent claims.

The Legal Foundation in India

Under Section 48 of the Patents Act, 1970, a patent holder in India has the exclusive right to prevent others from making, using, offering for sale, selling, or importing the patented product or process in India. An FTO analysis, conducted specifically for the Indian market, determines whether any such rights exist and whether they are enforceable against a planned commercial activity.

Patent protection is territorial. A patent granted in India protects the invention only within India. A patent granted in the US protects it only within the US. A company planning to manufacture in India and export to the US needs separate FTO analyses for both jurisdictions, because a product that is clear of Indian patent claims may still infringe an active US patent, or vice versa.

This is why an FTO search has to be jurisdiction-specific. A general search without defining the target market produces results that may be technically thorough but legally incomplete.

When to Commission an FTO Search

The question of when to conduct an FTO search is one that most businesses ask after they already need it. There are four points in a product's lifecycle where an FTO analysis consistently makes the most commercial sense.

The first is at the concept or early development stage. At this point, the product design is still flexible. If a blocking patent is identified early, the formulation, process, or design can often be adjusted without significant cost. The further along a product is in development when a blocking patent is found, the more expensive the response becomes.

The second is before a product launch. This is the most common trigger, and it is also the most expensive time to find a problem. Tooling is done, supply chains are set, marketing is planned. A blocking patent found here typically means a choice between launching and accepting litigation risk, stopping the launch, or emergency redesign under time pressure.

The third is before entering a new geographic market. A company that manufactures and sells in India and now wants to export to the EU or the US needs an FTO review for each new jurisdiction, because the patent landscape in each market is different.

The fourth is during mergers, acquisitions, and investment due diligence. When a company is acquiring a business or a technology portfolio, the IP risk embedded in the target company's products and processes is part of what is being acquired. An FTO analysis at this stage identifies whether the target's commercial activities carry undisclosed infringement exposure, which directly affects valuation and transaction risk.

What the FTO Search Involves

An FTO analysis is not a database keyword search. It is a structured technical and legal exercise that works through several layers.

The first layer is defining the product or process precisely. Before any search begins, the features of the product or process that are potentially patentable by third parties need to be identified and documented. A drug formulation, for instance, might have several distinct components: the active ingredient, the excipient composition, the manufacturing process, and the delivery mechanism. Each of these is a potential point of infringement and needs to be assessed separately.

The second layer is the search itself. The search covers granted patents and may also examine published patent applications to identify potential future risks in the target jurisdiction, using patent classification codes and technical keywords drawn from the product's features. The goal is to identify patents whose claims, at first reading, appear to cover any aspect of what the business plans to do.

The third layer is claim analysis. This is where most of the legal judgment happens. A patent's scope is defined entirely by its claims, not by its title, not by the abstract, and not by the description alone. Each claim that appears potentially relevant needs to be read carefully against the specific features of the product or process. The question at this stage is whether the product, as it would actually be manufactured or used, falls within the scope of any claim in any of the identified patents. This requires understanding both the technical content of the patent and how Indian (or the relevant jurisdiction's) courts have interpreted similar claim language.

The fourth layer is legal status verification. A patent that appears threatening on paper may already have expired, lapsed due to non-payment of renewal fees, been abandoned, or been invalidated through post-grant proceedings. Only enforceable patents create an immediate infringement risk, although published applications may also be reviewed to assess potential future exposure. Checking legal status is not a formality; it regularly removes patents from the risk list that would otherwise require detailed analysis.

The fifth layer is the FTO opinion. Once the search and analysis are complete, the findings are compiled into a written opinion that identifies which patents, if any, pose infringement risk, what the nature and degree of that risk is, and what options are available to address it.

What Happens When a Blocking Patent Is Found

Finding a potentially blocking patent is not the end of the road. It is the point at which the options need to be assessed.

The first option is a design-around. If the blocking patent's claims cover a specific feature of the product, the question is whether that feature can be changed in a way that takes the product outside the scope of the claims without compromising commercial viability. Design-arounds are often possible and, when executed correctly, permanently resolve the infringement risk without any negotiation with the patent holder.

The second option is licensing. If designing around is not practical, the business can approach the patent holder to negotiate a licence. This is a commercial negotiation, and the outcome depends on the relationship between the parties, the commercial value of the patent, and the leverage available on both sides. A willing licensor and a reasonable royalty rate may make this the fastest path to market.

The third option is challenging the patent's validity. If the blocking patent appears to have been granted incorrectly, because relevant prior art was not considered during examination or because the claimed invention did not actually meet the requirements of the Patents Act, the patent can be challenged through a post-grant opposition or a revocation proceeding. This is a longer and less certain route, but it is the right response when a patent should not have been granted in the first place.

The fourth option is accepting the risk. In some cases, the infringement risk identified may be low enough, because the claim scope is narrow, the patent is of doubtful validity, or the patent holder has no history of enforcement, that the business makes a considered commercial decision to proceed. This is a legitimate option, but it should be a deliberate decision made with full information, not an uninformed one made because the search was never conducted.

FTO in the Indian Pharmaceutical Context

The Indian pharmaceutical sector presents a specific set of FTO considerations that differ from other industries and from how pharmaceutical patents are managed in other jurisdictions.

India's patent landscape for pharmaceuticals is shaped by Section 3(d) of the Patents Act, which limits the ability of patent holders to obtain secondary patents on new forms of known drug molecules unless those new forms show significantly enhanced therapeutic efficacy. This means that a drug whose core molecule patent has expired may have fewer blocking secondary patents in India than the same drug has in the US or EU, where secondary patents on polymorphs, salts, and new formulations are more routinely granted.

For generic pharmaceutical companies and API manufacturers, this makes FTO searches in India a materially different exercise from FTO searches in Western markets. A formulation that would infringe multiple secondary patents in the US may face a materially different risk profile in India, once the relevant claims are assessed against Section 3(d) requirements and whether those secondary patents could survive an invalidity challenge on that ground.

Conversely, process patents in the pharmaceutical sector remain a significant source of FTO risk in India, even where product patents have expired or were never granted. A generic manufacturer using a patented manufacturing process to produce an off-patent molecule can still face an infringement claim if the process itself remains protected.

How an FTO Search Differs From a Patentability Search: Side by Side

A patentability search asks whether an invention can be protected. An FTO search asks whether a product can be commercialised.

A patentability search reviews prior art broadly to assess novelty and inventive step. An FTO search reviews active claims in in-force patents in a specific jurisdiction to assess infringement risk.

A patentability search supports a decision about whether to file a patent. An FTO search supports a decision about whether to manufacture, sell, or launch.

Both are important, and neither substitutes for the other. A company can have a strong, granted patent and still need an FTO clearance before it can use its own invention commercially.

M&P IP Protectors is an IPR law firm advising pharmaceutical, chemical, engineering, and technology companies on FTO searches and patent risk management across India and international jurisdictions. If you are planning a product launch, entering a new market, or acquiring a technology business, schedule a consultation with our patent attorneys to assess your IP exposure before it becomes a commercial problem.